Open Access

Identifying key genes and drug screening for preeclampsia based on gene expression profiles

  • Authors:
    • Zhengfang Xu
    • Chengjiang Wu
    • Yanqiu Liu
    • Nian Wang
    • Shujun Gao
    • Shali Qiu
    • Zhutao Wang
    • Jing Ding
    • Lubin Zhang
    • Hui Wang
    • Weijiang Wu
    • Bing Wan
    • Jun Yu
    • Jie Fang
    • Peifang Yang
    • Qixiang Shao
  • View Affiliations

  • Published online on: June 9, 2020     https://doi.org/10.3892/ol.2020.11721
  • Pages: 1585-1596
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Preeclampsia (PE) is characterized by gestational hypertension and proteinuria, and is a leading cause of maternal death and perinatal morbidity globally. Although the exact cause of PE remains unclear, several studies have suggested a role for abnormal expression of multiple genes. The aim of the present study was to identify key genes and related pathways, and to screen for drugs that regulate these genes for potential PE therapy. The GSE60438 dataset was acquired from the Gene Expression Omnibus database to analyze differentially expressed genes (DEGs). By constructing a protein‑protein interaction network and performing reverse transcription‑quantitative PCR verification, proteasome 26S subunit, non‑ATPase 14, prostaglandin E synthase 3 and ubiquinol‑cytochrome c reductase core protein 2 were identified as key genes in PE. In addition, PE was found to be associated with ‘circadian rhythm’, ‘fatty acid metabolism’, ‘DNA damage response detection of DNA damage’, ‘regulation of DNA repair’ and ‘endothelial cell development’. Through connectivity map analysis of DEGs, furosemide and droperidol were suggested to be therapeutic drugs that may target the hub genes for PE treatment. Results analysis of GSEA were included in the discussion section of this article. In conclusion, the current study identified novel key genes associated with the onset of PE and potential drugs for PE treatment.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu Z, Wu C, Liu Y, Wang N, Gao S, Qiu S, Wang Z, Ding J, Zhang L, Wang H, Wang H, et al: Identifying key genes and drug screening for preeclampsia based on gene expression profiles . Oncol Lett 20: 1585-1596, 2020
APA
Xu, Z., Wu, C., Liu, Y., Wang, N., Gao, S., Qiu, S. ... Shao, Q. (2020). Identifying key genes and drug screening for preeclampsia based on gene expression profiles . Oncology Letters, 20, 1585-1596. https://doi.org/10.3892/ol.2020.11721
MLA
Xu, Z., Wu, C., Liu, Y., Wang, N., Gao, S., Qiu, S., Wang, Z., Ding, J., Zhang, L., Wang, H., Wu, W., Wan, B., Yu, J., Fang, J., Yang, P., Shao, Q."Identifying key genes and drug screening for preeclampsia based on gene expression profiles ". Oncology Letters 20.2 (2020): 1585-1596.
Chicago
Xu, Z., Wu, C., Liu, Y., Wang, N., Gao, S., Qiu, S., Wang, Z., Ding, J., Zhang, L., Wang, H., Wu, W., Wan, B., Yu, J., Fang, J., Yang, P., Shao, Q."Identifying key genes and drug screening for preeclampsia based on gene expression profiles ". Oncology Letters 20, no. 2 (2020): 1585-1596. https://doi.org/10.3892/ol.2020.11721